ScottIA, HilmerSN, ReeveE, et al.: Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med, 2015; 175:827–834.
2.
SteinmanMA, MiaoY, BoscardinWJ, et al.: Prescribing quality in older veterans: A multifocal approach. J Gen Intern Med, 2014; 29:1379–1386.
3.
StoneNJ, RobinsonJG, LichtensteinAH, et al.: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol, 2014; 63:2889–2934.
4.
MannD, ReynoldsK, SmithD, MuntnerP: Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother, 2008; 42:1208–1215.
5.
LiemAH, Van BovenAJ, VeegerNJGM, et al.: Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial. Eur Heart J, 2002; 23:1931–1937.
6.
CannonCP, BaunwaldE, McCabeCH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350:1495–1504.
7.
PedersenT, KjekshusJ, BergK, et al.: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344:1383–1389.
8.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339:1349–1357.
9.
Marti-FabregasJ, GomisM, ArboixA, et al.: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke, 2004; 35:1117–1123.
10.
VollrathAM, SinclairC, HallenbeckJ: Discontinuing cardiovascular medications at the end of life: Lipid-lowering agents. J Palliat Med, 2005; 8:876–881.
11.
RussellBJ, RowettD, AbernethyAP, CurrowDC: Prescribing for comorbid disease in a palliative population: Focus on the use of lipid-lowering medications. Intern Med J, 2014; 44:177–184.
12.
SchwartzGG, OlssonAG, EzekowitzMD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA, 2001; 285:1711–1718.
13.
StenestrandU, WallentinL: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA, 2001; 285:430–436.
14.
HeeschenC, HammCW, LaufsU, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation, 2002; 105:446–452.
15.
SilveiraMJ, KazanisAS, ShevrinMP: Statins in the last six months of life: A recognizable, life-limiting condition does not decrease their use. J Palliat Med, 2008; 11:685–693.
16.
LaRosaJC, HeJ, VupputuriS: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA, 1999; 282:2340–2346.
17.
ThavendiranathanP, BagaiA, BrookhartMA, ChoudhryNK: Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials. Arch Intern Med, 2006; 166:2307–2313.
18.
KutnerJS, BlatchfordPJ, TaylorDH, et al.: Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: A randomized clinical trial. JAMA Intern Med, 2015; 175:691–700.
19.
SpencerFA, AllegroneJ, GoldbergRJ, et al.: Association of statin therapy with outcomes of acute coronary syndromes: The GRACE study. Ann Intern Med, 2004; 140:857–866.
